Neutropenia, thrombocytopenia, stomatitis, epistaxis, and hypertension occurred more frequently amongst patients treated with ramucirumab and FOLFIRI relative to placebo and FOLFIRI regardless of KRAS status or first-line TTP. The gene discussed is KRAS; the disease is neutropenia.